INSUBCONTINENT EXCLUSIVE:
Russian vaccine maker RDIF has tied up with Dr Reddy's Laboratories Ltd for clinical trial of Sputnik V Covid-19 vaccine in India
(Photo: Reuters/Representational image)The Russian Direct Investment Fund (RDIF) on Wednesday said it will supply Dr
It said the process will start soon after getting regulatory approval."Upon regulatory approval in India, RDIF shall supply to Dr
The Sputnik V vaccine, which is based on well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for
the coronavirus pandemic," RDIF said in a press release
| Russia seeking India's support to manufacture its Covid vaccine Sputnik V: Sources"Deliveries could potentially begin in late 2020
subject to completion of successful trials and registration of the vaccine by regulatory authorities in India," it added.Kirill Dmitriev,
India is amongst most severely impacted countries from Covid-19 and we believe our human adenovirus dual vector platform will provide a safe
and scientifically validated option to India in the battle against Covid-19."GV Prasad, Co-Chairman and Managing Director of Dr
The Phase I and II results have shown promise, and we will be conducting Phase-III trials in India to meet the requirements of the Indian
Gamaleya National Research Institute of Epidemiology and Microbiology on August 11
adenoviral vectors platform.However, several medical experts and sceintists around the globe had earlier raised doubts over Russia's
Covid-19 vaccinedue to lack of transparency regarding trial data
| If all goes well, India will get Covid-19 vaccine by end of this year: Health Minister
